Eupraxia Pharmaceuticals EPRX
NASDAQ EPRX
$9.00 +0.69 (+8.37%)
As of: Sep 30, 2026 · 12:05 PM EDT

Eupraxia Pharmaceuticals (EPRX) Net Cash Flow (2023 - 2025)

Updated

Eupraxia Pharmaceuticals (EPRX) posted Net Cash Flow of -$8.43 million for the quarter ended Dec 31, 2025, compared with $25.71 million a year earlier.

Analysis

Eupraxia Pharmaceuticals (EPRX) Net Cash Flow (2023 - 2025) Analysis & Trends

For the year ended Dec 31, 2025, Eupraxia Pharmaceuticals' Net Cash Flow came in at $46.92 million, up 198.6% from the prior year.

  • Annual Net Cash Flow shows a three-year compound annual growth rate of 95.9% (years ended Dec 2022 to Dec 2025).
  • In prior years, Eupraxia Pharmaceuticals' Net Cash Flow was $15.71 million in the year ended Dec 31, 2024, $256,970 in the year ended Dec 31, 2023 (-95.9%) and $6.24 million in the year ended Dec 31, 2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) NCF (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn -1.27 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn -2.82 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn 1.53 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn 757.00 Mn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn 1.62 Bn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn 1.95 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn -4.43 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn -722.00 Mn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn 652.90 Mn
10 Eupraxia Pharmaceuticals 328.04 Mn 326.44 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 -8.43 Mn
Dec 31, 2024 25.71 Mn
Dec 31, 2023 -6.01 Mn
Sep 30, 2023 10.33 Mn
API Access

Eupraxia Pharmaceuticals Net Cash Flow API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=net-cash-flow&ticker=EPRX&period=max&api_key=YOUR_API_KEY